RecruitingPhase 1NCT07230353

A Phase 1b Open-label Study to Evaluate Safety in Participants With Rheumatoid Arthritis

A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis

Sponsor

Xencor, Inc.

Enrollment

47 participants

Start Date

Oct 21, 2025

Study Type

INTERVENTIONAL

Conditions

Rheumatoid Arthritis

Summary

The purpose of this study is to determine the safety and tolerability of XmAb13676 in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening
Inadequate response to, loss of response to, or intolerance to available RA therapies.
Stable doses of RA medications prior to screening
Use of highly effective methods of contraception

Exclusion Criteria5

Major surgery within 12 weeks prior to screening or planned within 12 months after dosing
Recurrent infections or active clinically significant infection
Active or untreated latent tuberculosis
Cancer or history of cancer or lymphoproliferative disease within the previous 5 years
Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease